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Abstract 
The Malaria Policy Advisory Committee (MPAC) to the World Health Organization held its eighth meeting in Geneva, 
Switzerland from 16 to 18 September 2015. This article provides a summary of the discussions, conclusions and meet-
ing recommendations. Meeting sessions included: recommendations from the Evidence Review Group (ERG) on mass 
drug administration; recommendations from the ERG on malaria in pregnancy; recommendations on when to scale 
back vector control; feedback on the Plasmodium vivax technical brief and the recommendation for G6PD testing 
before treatment; updates on artemisinin and artemisinin-based combination therapy resistance and the Greater 
Mekong Subregion elimination strategy; an update from the working group on malaria terminology; and updates 
on malaria elimination in the World Health Organization European region, the ERG on malaria elimination, and World 
Health Organization reform to support innovation, efficiency and quality in vector control tools. Policy statements, 
position statements, and guidelines that arise from the MPAC meeting conclusions and recommendations will be 
issued formally and disseminated to World Health Organization Member States by the World Health Organization 
Global Malaria Programme.
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Background
The Malaria Policy Advisory Committee (MPAC) to the 
World Health Organization (WHO) held its eighth bian-
nual meeting from 16 to 18 Sep 2015 in Geneva, Switzer-
land, following its meetings in February and September 
2012, March and September 2013, March and September 
2014, and March 2015 [1–7]. This article provides a sum-
mary of the discussions, conclusions and recommenda-
tions from the September 2015 meeting1 as part of the 
Malaria Journal thematic series “WHO global malaria 
recommendations” [8].
The following sections of this article provide details 
and references for the meeting sessions on: mass drug 
administration; malaria in pregnancy; when to scale back 
vector control; the Plasmodium vivax technical brief and 
1 The complete set of all MPAC September 2015 meeting-related docu-
ments including background papers, presentations, and member declara-
tions of interest can be found online at http://www.who.int/malaria/mpac/
sep2015/en/.
the recommendation for G6PD testing before treatment; 
artemisinin and artemisinin-based combination therapy 
(ACT) resistance and the Greater Mekong Subregion 
elimination strategy; malaria terminology; malaria elimi-
nation; and WHO reform to support innovation, effi-
ciency and quality in vector control tools.
The MPAC discussion and recommendations related to 
these topics, which took place partially in closed session, 
are also included. MPAC decisions are reached by con-
sensus [9]. The next meeting of the MPAC will be held on 
16–18 Mar 2016 [10].
Report from the WHO Global Malaria Programme
Following a welcome by the Chair of MPAC, the Director 
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provided MPAC members with an update on WHO-
GMP’s activities since their last meeting [11]. Most 
importantly, the WHO Global Technical Strategy for 
Malaria (2016–2030) was endorsed by the World Health 
Assembly in Geneva in May 2015 [12, 13] and, together 
with the companion document Action and Investment to 
defeat Malaria (2016–2030) [14] developed by the Roll 
Back Malaria (RBM) partnership, was jointly launched 
at the third International Conference on Financing for 
Development in Addis Ababa in July 2015. Regional 
implementation plans are currently under develop-
ment and, with the exception of the European region, all 
regional consultations will take place by the end of 2015.
The Director’s report included an overview of antici-
pated guidance due in 2016 as well as guidance published 
on the WHO-GMP website since the last MPAC meet-
ing in March. Guidance published in 2015 included the 
third edition of the WHO Guidelines for the treatment of 
malaria [15], the second edition of the operational man-
ual for indoor residual spraying (IRS) for malaria trans-
mission, control and elimination [16], a case study of the 
successful elimination and prevention of re-establish-
ment of malaria in Tunisia [17], and the technical brief on 
the control and elimination of P. vivax malaria [18].
The Director provided an update on the new WHO-
GMP departmental structure and its strategic priorities 
which are in line with the goals and targets of the new 
WHO Global Technical Strategy for Malaria (2016–
2030). The new matrix structure includes the four exist-
ing but re-named units—drug efficacy and response; 
prevention, diagnostics and treatment; surveillance, 
monitoring and evaluation; and, entomology and vector 
control—together with three new cross-cutting units—
strategy, evidence and economics; elimination; and, 
technical support and capacity building. Two team lead 
positions are currently under recruitment: Elimination, 
and Surveillance, Monitoring and Evaluation.
Updates from the WHO Regional Offices highlighted 
the key message of a global malaria situation where 
there has been both progress and challenges. For exam-
ple, in the Americas region, with the exception of Haiti 
and Venezuela, all countries showed an overall 50–100 % 
decrease in malaria morbidity since 2000. However, some 
of these gains were unstable, with substantial yearly fluc-
tuations. A similar scenario was present in the Eastern 
Mediterranean region; the European region has reported 
no cases since 2014. In the African region, even though 
malaria incidence decreased by 34  % and malaria mor-
tality declined by 54 % from 2000 to 2013, huge gaps in 
intervention coverage still remain. For example, in 2013, 
only 29 % of households had enough insecticide-treated 
mosquito nets (ITNs) for all household members. Cover-
ing all populations at risk for malaria, especially mobile 
or migrant populations, is a particular challenge in the 
South-East Asian and Western Pacific regions as well.
The WHO-GMP Director provided updates to MPAC 
members on the changes that are being implemented 
across the WHO-GMP’s Technical Expert Groups 
(TEGs), in order to align them with the department’s new 
organizational structure. There will be five TEGs in all: 
chemotherapy; antimalarial drug efficacy and Response; 
vector control; surveillance, monitoring and evaluation; 
and financing, coverage and impact. Their terms of ref-
erence and membership are currently being reviewed. 
The Director also announced a new effort, to be launched 
soon and conducted over the next few years, to define 
and understand the implications of various determinants 
(including those beyond health, such as climate change) 
on the potential for malaria eradication. More details on 
this study group will be announced shortly.
Recommendations from the Evidence Review Group 
on mass drug administration (MDA)
Mass drug administration (MDA) has received renewed 
interest from countries and funders over the past decade 
in the context of malaria elimination, as part of multidrug 
resistance containment, and more recently in emergency 
situations such as the West African Ebola outbreak. To 
assist in updating WHO recommendations developed in 
2010, WHO-GMP convened an Evidence Review Group 
(ERG). This ERG met from 20 to 22 Apr 2015 to review 
recent published and unpublished evidence on the use of 
MDA, mass screening and treatment (MSAT) and focal 
screening and treatment (FSAT) in specific epidemiologi-
cal settings.
The specific objectives of the ERG were to:
1. Review all available published and unpublished 
reports on the impact of MDA, MSAT and FSAT 
on malaria transmission, building on the recent 
Cochrane review, and a recent qualitative review.
2. Review the results of experiences and unpublished 
studies of large-scale implementation of MDA in 
Comoros, Sierra Leone, the Myanmar-Thai border, 
Vanuatu and Viet Nam and of MSAT and FSAT in 
Cambodia, Kenya, Zambia and Zanzibar.
3. Evaluate the role of the concomitant administration 
of single low-dose primaquine (PQ) (0.25  mg base/
kg) as a Plasmodium falciparum gametocytocide, 
together with the artemisinin-based combination 
therapy (ACT) deployed for MDA.
4. Define the specific conditions for application of 
MDA, MSAT and FSAT to reduce malaria transmis-
sion in terms of endemicity, medicines and dosages, 
use of diagnostics, timings and number of MDA 
rounds, concomitant implementation of vector-
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control measures, and optimum strategies to ensure 
community uptake and pharmacovigilance.
5. Identify research gaps and provide recommendations 
on data requirements, study methods and ethical 
considerations for research groups and policy-mak-
ers interested in further evaluating the role of MDA, 
MSAT and FSAT in reducing malaria transmission.
The full ERG meeting report [19] and supporting back-
ground documentation [20] are available on the WHO-
GMP website.
MPAC members thanked the ERG for the thorough-
ness of their evidence review, and for the subsequent 
work on grading of the evidence [21], modelling [22] and 
costing [23] of MDA programmes, which was also pre-
sented. General points raised during the MPAC discus-
sion included: the need for a clear objective for MDA and 
a clear definition of the target population, the method 
and duration of delivery, and post-MDA activities; that 
MDA should be combined with other malaria control 
activities to sustain the gains, particularly in reducing the 
vectorial capacity, and to make use of existing delivery 
systems where possible; and that community engagement 
is essential for successful MDA campaigns. Discussion 
based on the modelling data stressed the importance of 
effective coverage, which is likely to be more important 
than the number and timing of rounds. In addition, MDA 
appeared to be more effective in low than high transmis-
sion situations, but optimum timing was dependent upon 
the objective of the MDA, for example, interruption of 
transmission versus morbidity reduction.
MPAC concluded that although there is generally weak 
evidence on which to base recommendations, there is a 
need to provide the global malaria community with some 
guidance. As a result, MDA is recommended only in the 
very specific circumstances outlined below.
Following MPAC input during the closed session of the 
meeting, WHO-GMP has published the following rec-
ommendations, which are available in full on their web-
site [24]:
1. Use of MDA for the elimination of P. falciparum 
malaria can be considered in areas approaching inter-
ruption of transmission where there is good access to 
treatment, effective implementation of vector control 
and surveillance, and a minimal risk of re-introduc-
tion of infection.
2. Given the threat of multidrug resistance and the 
WHO call for malaria elimination in the Greater 
Mekong Subregion (GMS), MDA may be considered 
as a component of accelerated malaria elimination 
efforts in areas of the GMS with good access to treat-
ment, vector control and surveillance.
3. Use of time-limited MDA to rapidly reduce malaria 
morbidity and mortality may be considered for epi-
demic control as part of the initial response, along 
with the urgent introduction of other interventions.
4. Use of time-limited MDA to reduce malaria morbid-
ity and mortality may be considered during excep-
tional circumstances when the health system is 
overwhelmed and unable to serve the affected com-
munities.
5. In the absence of sufficient evidence, WHO does not 
recommend the use of MDA in situations other than 
for areas approaching elimination, epidemics, and 
complex emergencies, as specified above (see 1–4).
6. Mass primaquine prophylactic treatment, requiring 
pre-seasonal MDA with daily administration of pri-
maquine for two weeks without G6PD testing, is not 
recommended for the interruption of P. vivax trans-
mission.
7. Mass screening and treatment and focal screening 
and treatment for malaria are not recommended as 
interventions to interrupt malaria transmission.
8. Medicines used for MDA must be of proven effi-
cacy in the implementation area and preferably have 
a long half-life. WHO recommends that a medicine 
different from that used for first line treatment be 
used for MDA. Programmes should include monitor-
ing of efficacy, safety and the potential emergence of 
resistance to the antimalarial medicines deployed for 
MDA.
9. WHO supports the need for more research on the 
optimum methods of implementing MDA pro-
grammes, promoting community participation and 
compliance with treatment, and evaluating their 
effectiveness. Modelling can help guide the optimum 
method of administering MDA in different epidemi-
ological circumstances and predict its likely impact.
Recommendations from the Evidence Review Group 
on malaria in pregnancy
Because malaria in pregnancy (MiP) is a major, preventa-
ble cause of maternal morbidity and poor birth outcomes, 
WHO recommends the use of ITNs, effective case man-
agement of malaria and anaemia in pregnant women, 
and in areas of moderate to high malaria transmission in 
sub-Saharan Africa, intermittent preventive treatment in 
pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP). 
In recent years, an alternative preventive strategy—inter-
mittent screening and treatment in pregnancy (ISTp) 
using rapid diagnostic tests (RDTs) and ACT during 
antenatal care (ANC) visits—has been evaluated in sev-
eral countries. Moreover, multiple recent studies have 
assessed the safety of using ACTs in the first trimester of 
pregnancy. WHO convened an ERG in Geneva from 13 
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to 16 Jul 2015 to review this new evidence and develop 
recommendations on the efficacy and cost-effectiveness 
of (ISTp) compared to IPTp-SP for the prevention of MiP, 
and on the safety of ACTs for malaria treatment in the 
first trimester of pregnancy.
The objectives of the ERG were to:
(a) Compare ISTp with IPTp-SP, specifically:
1. Review all available published and unpublished 
reports on the efficacy and safety of ISTp compared 
to IPTp for prevention of the adverse consequences 
of MiP.
2. Review all available reports on the acceptability of 
ISTp under trial conditions.
3. Review results of cost-effectiveness analyses (CEA) of 
ISTp.
4. Review the recent evidence on the effect of sub-
microscopic infections on maternal and infant out-
comes.
5. Review available published and unpublished reports 
on the impact of SP resistance on the effectiveness of 
IPTp-SP.
6. Review results of recently completed clinical trials 
evaluating the efficacy and safety of dihydroarte-
misinin-piperaquine (DHA-PPQ) for IPTp.
7. Based on the evidence reviewed, consider whether 
either ISTp or IPTp-DHA-PPQ could be recom-
mended as a potential alternative to IPTp-SP in some 
areas with high SP resistance and/or very low trans-
mission.
(b) Review the safety of ACT in early pregnancy, 
specifically:
1. Review the evidence of embryotoxicity of artemisinin 
derivatives from animal studies.
2. Review available published and unpublished reports 
on exposures to artemisinin derivatives in the first 
trimester of pregnancy compared to other anti-
malarial medicines.
3. Review results of recent clinical trials evaluating the 
efficacy and safety of different artemisinin-based 
combinations for malaria treatment in the second 
and third trimester of pregnancy.
4. Based on the evidence reviewed, consider whether 
the current WHO recommendations on use of ACT 
in the first trimester of pregnancy could be updated.
The full meeting report [25] is available on the WHO-
GMP website. In summary, the ERG concluded that ISTp 
should not be recommended as an alternative to IPTp-SP, 
which remains highly cost effective, and ACT compared 
to quinine appear to be comparably safe to use in the first 
trimester of pregnancy, although as with all drug expo-
sures, there is a need for continued pharmacovigilance.
MPAC thanked the MiP ERG for their efforts. WHO-
GMP will continue to promote the adoption and imple-
mentation of the updated IPTp-SP recommendation [26], 
and encouraged scaling-up coverage of three or more doses 
of IPTp-SP. In addition, MPAC recommended that new 
data on miscarriage and congenital malformations follow-
ing exposure to artemisinin derivatives in the first trimester 
of pregnancy should be included in the update of the WHO 
Guidelines for the treatment of malaria [15], and follow the 
process established by WHO so that ACTs may be consid-
ered for inclusion as a first-line therapeutic option.
While WHO-GMP works to formally update the online 
version of the guidelines through the appropriate mecha-
nisms, MPAC’s recommendations [27] are listed below:
1. Recent comparative studies have shown that inter-
mittent screening and treatment in pregnancy (ISTp) 
with RDTs and ACT resulted in a higher propor-
tion of maternal infections and clinical malaria dur-
ing pregnancy compared to intermittent preventive 
treatment in pregnancy (IPTp) with SP given dur-
ing ANC visits. The effects of ISTp on birth weight 
varied. In some studies, ISTp with artemether-lume-
fantrine was not inferior to IPTp in preventing low 
birth weight. In other studies, ISTp with dihydroar-
temisinin-piperaquine (DHA-PPQ) resulted in a 
lower mean birth weight compared with IPTp-SP in 
paucigravidae in areas of high malaria transmission 
and high SP resistance. ISTp is also less cost-effective 
than IPTp-SP and, for these reasons, it is not recom-
mended as an alternative to IPTp-SP.
2. IPTp-SP remains highly cost-effective in preventing 
the adverse consequences of malaria on maternal 
and fetal outcomes, and should, therefore, be actively 
scaled up in line with the current WHO recom-
mendations. IPTp-SP also remains effective in areas 
where quintuple-mutant haplotypes of P. falciparum 
to SP are highly prevalent. Further research on the 
relationship of SP resistance markers and IPTp effec-
tiveness should be done, particularly in areas where 
transmission and thus maternal immunity have 
declined substantially in recent years.
3. The threshold level of malaria transmission below 
which IPTp-SP is no longer cost-effective has not 
been identified. Therefore, in areas where IPTp-SP is 
implemented and transmission has been reduced to 
low levels as a result of successful control strategies, 
WHO recommends continued IPTp-SP implementa-
tion until the area approaches interruption of trans-
mission.
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4. An association between sextuple mutant haplotypes 
of P. falciparum and decreased birth weight has been 
reported in observational studies in a few sites in East 
Africa. Further studies are required to assess this and 
to devise the best and most cost-effective prevention 
strategies in areas of very high SP resistance. One 
potential strategy to be tested is to provide a single 
RDT screening and ACT treatment at the first ANC 
visit during the second trimester, in addition to the 
continued delivery of IPTp-SP.
5. Recent studies have shown that IPTp with DHA-PPQ 
does not reduce the incidence of low birth weight 
compared to IPTp-SP, but that it is more efficacious 
in reducing maternal malaria parasitaemia and anae-
mia at delivery, incidence of malaria infection and 
clinical malaria during pregnancy, and stillbirths and 
early infant mortality (i.e., within 6–8 weeks). More 
research is needed to evaluate the impact of DHA-
PPQ for IPTp in preventing low birth weight, safety 
of repeated doses, and adherence to the required 
3-day regimen.
6. New evidence from 1025 pregnancies with confirmed 
artemisinin exposure in the first trimester in South-
East Asia and sub-Saharan Africa indicates that arte-
misinins are not associated with an increased risk 
of miscarriage, stillbirths or major congenital mal-
formations compared to non-artemisinin regimens. 
Moreover, comparison of carefully documented 
and prospectively collected safety data on women 
exposed only to artemisinin-based treatment with 
data collected on women exposed only to quinine 
in the first trimester of pregnancy showed that arte-
misinin was associated with a significantly reduced 
rate of miscarriage compared to quinine. MPAC rec-
ommends the review of the WHO Guidelines for the 
treatment of malaria to consider the timely inclusion 
of ACT as a first-line therapeutic option for uncom-
plicated falciparum malaria.
Recommendations on when to scale back vector control
Members of the Vector Control Technical Expert Group 
(VC TEG) and the WHO-GMP Secretariat presented 
their conclusions from a comprehensive literature review 
and mathematical simulation model on when to scale 
back vector control, a core component of malaria pre-
vention, in areas where malaria transmission has been 
reduced [28]. WHO currently recommends universal 
coverage with effective vector control for all persons at 
risk of malaria. Universal coverage is defined as one ITN 
for every two persons at risk of malaria, and the popula-
tion at risk (defined periodically on a sub-national level) 
includes all persons in geographical areas or localities 
with ongoing malaria transmission.
Since 2000, substantial expansion of funding has ena-
bled significant scaling up of malaria prevention, diag-
nostic testing and treatment. However, given the general 
decline in malaria transmission in many settings, WHO 
Member States have recently requested guidance from 
WHO-GMP on the circumstances under which it may 
be appropriate to scale back vector control interven-
tions to targeted deployment in specific geographic areas. 
This request has been prompted largely by the recogni-
tion that the epidemiology of malaria has been altered in 
some settings as a result of years of sustained, effective, 
malaria control. However, there is a concern that this 
may lead to a perception that the discontinuation of vec-
tor-control implementation in such settings will be asso-
ciated with a minimal risk of resurgence, and that such 
scale-back is an appropriate way for malaria programmes 
to better allocate resources.
The modelled scenarios presented to MPAC examined 
the epidemiological implications of reducing the cov-
erage of ITNs and IRS to no coverage under conditions 
of differing levels of: (a) baseline (i.e., pre-intervention) 
entomological inoculation rates (EIR); (b) infection 
importation rates; (c) disease surveillance coverage; and 
(d) case management coverage. The results, highlighted 
in greater detail in the meeting presentation itself and 
available online [29], indicated that the scale-back of 
malaria vector control was associated with a high prob-
ability of malaria resurgence, including most areas in 
which malaria transmission was very low or had been 
interrupted (i.e., no local transmission). Even in areas 
where there are substantial reductions in malaria trans-
mission (indicated by an annual incidence of <1 local 
case per 1000 population), discontinuing vector control 
conferred a high risk of malaria resurgence in most situ-
ations, This risk increased in contexts of relatively high 
receptivity (defined as the ability of an ecosystem to 
allow transmission of malaria), high rates of vulnerability 
(defined as the frequency of influx of infected individuals 
or groups and/or infective anophelines), and low cover-
age of disease surveillance and case management.
The analysis found that the situations with a high prob-
ability of resurgence were likely to correspond most 
closely with malaria-endemic areas of sub-Saharan 
Africa. The probability of resurgence was low only in 
scenarios with low historic EIRs, low infection importa-
tion rates, and high coverage of both disease surveillance 
and case management. Such scenarios are found mainly 
in countries outside of sub-Saharan Africa that are cur-
rently experiencing very low malaria incidence. The pre-
cise measures of malaria receptivity, vulnerability, and 
the levels of these parameters at which scale-back of vec-
tor control caries minimal risk of resurgence, still remain 
to be comprehensively defined. Similarly, it is difficult 
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to predict whether zero local transmission can be main-
tained in the absence of vector control. Moreover, where 
there has been minimal change in inherent malaria trans-
mission potential, the stability of the malaria parasite–
vector relationship following interruption of malaria is 
not well understood. Further evaluations of the specific 
criteria for identifying areas where vector-control scale-
back would carry a low risk of malaria resurgence are, 
therefore, required before further conclusions can be 
drawn.
MPAC made suggestions to better refine definitions 
for receptivity and vulnerability so that they matched 
updated malaria terminology (these have been reflected 
in the summary above), and to clarify a few points in 
the main text. The wording of the recommendations 
emphasizes the definition of what an “area” is (i.e., it is 
to be based on the availability of reliable disaggregated 
disease surveillance data and feasibility for decisions on 
vector control implementation—and not necessarily on 
administrative boundaries). This embraces the concept of 
geographical targeting of vector control, including invest-
ments in entomological monitoring as part of any scale-
back. Because the recommendations build on current 
policy—WHO continues to recommend effective vec-
tor control in areas where there continues to be malaria 
transmission while acknowledging that new vector con-
trol tools are urgently needed—they are published in the 
form of an information note to assist countries, and their 
funders, to translate these in the planning and implemen-
tation for malaria control programmes [30].
The information note contains the following 
recommendations:
1. In areas with ongoing local malaria transmission 
(irrespective of both the pre-intervention and the 
current level of transmission), the scale-back of vec-
tor control is not recommended. Universal coverage 
with effective malaria vector control (including the 
use of new vector control tools when they become 
available) of all persons in such areas should be pur-
sued and maintained.
2. In areas where transmission has been interrupted, 
the scale-back of vector control should be based on 
a detailed analysis that includes assessment of the 
receptivity and vulnerability, active disease surveil-
lance system, and capacity for case management and 
vector control response.
3. Countries and partners should invest in health sys-
tems particularly in the strengthening of disease and 
entomological surveillance, as identification of areas 
for geographical scale-back as well as timely detec-
tion and appropriate response to resurgence depend 
on this capacity.
MPAC members underscored the critical need for all 
countries with ongoing malaria transmission, and in 
particular those approaching elimination, to build and 
maintain strong capacity in disease and entomological 
monitoring in order to provide useful setting-specific 
information on which to base decisions, including the 
ability to respond to possible resurgences. For example, in 
areas where transmission has been reduced significantly, 
active case detection will be needed because at this stage 
every case matters and so should be found, treated, and 
reported. Such capacity will be a pre-condition for evalu-
ating the potential for geographical scale-back of vector 
control.
Feedback on the section of the Plasmodium vivax technical 
brief related to recommendation for G6PD testing 
before radical cure with primaquine
The WHO Guidelines for the treatment of malaria [15] 
contain recommendations for the treatment of P. vivax 
and Plasmodium ovale that are based on the need to radi-
cally cure patients using primaquine (the only available 
anti-relapse medicine) while at the same time minimizing 
the risk of primaquine-induced acute haemolysis in those 
who are deficient in the enzyme glucose-6-phospate 
dehydrogenase (G6PD). The guidelines recommend 
that patients with confirmed P. vivax or P. ovale malaria 
who are not aware of their G6PD status should be tested 
before the administration of radical cure with pri-
maquine. The guidelines provide recommendations for 
primaquine anti-relapse therapy in both G6PD normal 
and G6PD deficient patients. In addition, the guidelines 
also specify that when G6PD testing is not available, a 
decision to administer or withhold primaquine may still 
have to be based on weighing the benefits of radical cure 
against the haemolytic risk posed by primaquine.
These recommendations on the radical cure of P. vivax 
infections are also reiterated in Control and elimination 
of Plasmodium vivax malaria—A technical brief [18], a 
WHO-GMP publication that deals exclusively with the 
control and elimination of P. vivax malaria. This techni-
cal brief was launched on 29 Jul 2015 at a global meeting 
held in New Delhi that was attended by countries in all 
WHO Regions with endemic P. vivax malaria. The launch 
was followed by a 2-day meeting in which participating 
countries deliberated on the translation of the guidelines 
into policy and strategy for their national malaria control 
programmes (NMCPs). The meeting brought to light two 
main issues that will make implementing the WHO rec-
ommendations challenging. They are:
(a)  The limited availability of a robust, easy-to-use, 
point-of-care G6PD test restricts the ability to 
deploy primaquine for radical cure at the primary 
Page 7 of 12WHO Malaria Policy Advisory Committee and Secretariat  Malar J  (2016) 15:117 
health care level. Promoting referral to higher level 
facilities where primaquine can be administered 
safely and G6PD testing performed would therefore 
need to be more explicit in the current recommen-
dations so as not to compromise the schizonticidal 
treatment for P. vivax that is ongoing at the primary 
level. At present only early treatment of blood-stage 
infection can be accessed in peripheral health care 
settings, including at the community level.
(b) Some countries, particularly (but not only) in the 
Region of the Americas, are currently implement-
ing radical cure for all patients at health facility level 
without testing for G6PD. The rationale for this 
approach is that the G6PD deficiency allele frequency 
is low in these areas, and therefore the benefits of 
providing primaquine radical cure for all P. vivax 
patients exceed the risk of primaquine-induced hae-
molysis. In these settings, full compliance with the 
new recommendation of testing before treatment 
could affect progress in the control of P. vivax malaria 
and potentially reverse the progress made.
The main conclusion from the Delhi meeting, which 
were summarized and presented to MPAC [31], were 
that there is a need for additional practical guidance from 
WHO-GMP to countries on:
(a)  How NMCPs could progressively introduce qual-
ity G6PD tests that are currently available for all 
confirmed P. vivax patients before providing them 
with primaquine radical cure without compromis-
ing the existing and ongoing programmes aimed at 
achieving greater coverage for P. vivax treatment in 
general. Learning from early deployment can help 
when expanding the introduction of G6PD testing 
to areas where it is currently not deployed.
(b)  How to perform a risk–benefit analysis at national 
level on administering primaquine radical cure 
when a patient’s G6PD status is unknown, consid-
ering the prevalence and type of G6PD deficiency 
in the country, the frequency and risk of P. vivax 
relapses, the availability of point of care G6PD tests, 
the capacity to interpret those tests correctly, and 
the capacity of the health care system to detect and 
manage the risk of primaquine-induced haemolysis.
MPAC members agreed with the feedback provided by 
P. vivax endemic countries and supported their request 
for additional guidance from WHO-GMP. Their advice 
to WHO-GMP was for the current WHO recommenda-
tions to remain unchanged in the WHO Guidelines for 
the treatment of malaria, which should serve as a pri-
mary source document, and that the P. vivax technical 
brief and any other similar subsequent documents always 
refer to the WHO Guidelines for the treatment of malaria 
[15]. It was recommended that WHO-GMP produce 
additional implementation guidance to assist countries 
with the practicalities of G6PG testing.
Update on artemisinin and ACT resistance with special 
focus on the Greater Mekong Subregion (GMS), 
including the GMS elimination strategy
WHO-GMP updated MPAC members on the current 
status of artemisinin and ACT resistance, which is avail-
able on the WHO-GMP website [32]. Of particular inter-
est was the response to artemisinin resistance and move 
towards the goal of malaria elimination in the GMS, 
where the incidence of malaria has been greatly reduced 
over the past 10–20  years. However, this has been cou-
pled with concern that in certain areas within the GMS, 
P. falciparum is becoming increasingly resistant to anti-
malarial medicines. The current situation is particularly 
worrisome at the border between Cambodia and Thai-
land, where P. falciparum could become untreatable 
within a few years. In addition, molecular studies have 
confirmed that artemisinin resistance has emerged inde-
pendently in multiple areas of the GMS. In response, 
MPAC recommended at its September 2014 meeting 
the adoption of the goal of elimination of P. falciparum 
in the GMS by 2030. Subsequently, at the World Health 
Assembly in May 2015, WHO-GMP launched a Strategy 
for malaria elimination in the Greater Mekong subregion 
(2015–2030) [33], which was endorsed by all the GMS 
countries (Cambodia, Lao People’s Democratic Republic, 
Myanmar, Thailand, Viet Nam). An update on progress of 
the strategy implementation was given [34].
Some of the highlights from GMS country updates [35] 
on ACT efficacy were:
(a)  Cambodia: a consensus meeting on the national 
treatment policy for P. falciparum was held in 
January 2014. As a result, artesunate-mefloquine 
(ASMQ) has been re-introduced as first-line treat-
ment, replacing dihydroartemisinin-piperaquine 
(DHA-PPQ), since the proportion of P. falciparum 
strains with multiple pfmdr1 copy numbers (which 
confer mefloquine resistance) is currently minimal 
in the area.
(b) Lao People’s Democratic Republic: the emergence of 
artemisinin resistance in southern Lao PDR is sup-
ported by the identification in 2013 of the presence 
of k13 mutants (mainly C580Y and R539T) in the 
circulating parasite populations. However, the ther-
apeutic efficacy of artemether-lumefantrine (AL) 
has not been affected, and cure rates have remained 
high since 2005. Containment activities started in 
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2014, and therapeutic efficacy studies (TES) are 
now being conducted in Attapeu, Champasak and 
Sekong provinces.
(c)  Myanmar: studies evaluating the presence of k13 
mutants have shown that the predominant k13 
mutant found in Myanmar is likely to have arisen 
independently rather than to have spread from 
Cambodia. A new k13 propeller polymorphism 
(F446I) associated with delayed parasite clearance 
was detected as early as 2013 along both the China–
Myanmar border and the India–Myanmar border. 
Research is ongoing to validate the role of this new 
mutant in artemisinin resistance but preliminary 
results suggest that the F446I mutation is associated 
with a lower level of artemisinin resistance com-
pared to C580Y. However, despite a high prevalence 
of the k13 F446I in Myanmar, ACT efficacy remains 
high on both sides of the border between India and 
Myanmar.
(d) Thailand: during a consensus meeting held in 2015, 
DHA-PPQ became the first-line treatment in the 
country, and its efficacy is currently being evaluated.
(e)  Viet Nam: TES conducted since 2010 using DHA-
PPQ reported a treatment efficacy of more than 
95 %, despite a day-3 positivity rate of up to 36 %.
WHO-GMP stressed that despite the delayed parasite 
clearance associated with artemisinin resistance in some 
areas of the GMS, ACT still remains the most effective 
treatment for uncomplicated P. falciparum malaria. Most 
patients with delayed parasite clearance are cured, as 
long as the partner drug remains effective. It is impera-
tive that routine monitoring of therapeutic efficacy 
continues to ensure that the recommended ACT is effec-
tive, that changes in national treatment policies can be 
implemented in a timely manner, and that artemisinin 
resistance can be detected early. The assessment of K-13 
propeller-region mutants will greatly facilitate the track-
ing of artemisinin resistance as it emerges.
Given the commitment to eliminate P. falciparum 
malaria in the GMS set out in the recently launched 
Strategy for malaria elimination in the Greater Mekong 
Subregion (2015–2030) [33], MPAC was provided with an 
update from the Coordinator of the emergency response 
to artemisinin resistance (ERAR) and Mekong Malaria 
Elimination Hub [36]. The update outlined the goals, 
objectives, milestones, targets and main interventions 
of the strategy, including progress with the roll out of 
the strategy. Because the strategy was only launched in 
May, the development and adaptation of national malaria 
elimination strategies to fall in line with the overall strat-
egy is ongoing. Ongoing activities include setting up the 
appropriate regional governance structures, conducting 
training, and surveillance, monitoring and evaluation. 
MPAC members were pleased to see the improvement 
in surveillance in the region, including the collection of 
the baseline information needed for the GMS elimination 
strategy. However, in future they requested that WHO-
GMP schedules more time for GMS elimination strategy 
updates, which will feature more detailed and up-to-date 
data on progress and challenges.
Malaria terminology
MPAC members welcomed the WHO-GMP initiative to 
update the WHO publication, Terminology of malaria 
and of malaria eradication, which dates back to 1963. 
Several WHO publications over the past 10  years have 
included a glossary of terms related to malaria preven-
tion, control, elimination and surveillance. However, 
the terminology of malaria has not been comprehen-
sively reviewed for 50 years and is in need of an update, 
to archive terms no longer in use, and to clarify terms 
so that they can be consistent in meaning across 
documents.
WHO-GMP has taken a phased approach in updating 
malaria terminology, further details of which are avail-
able on the WHO-GMP website as part of the MPAC 
meeting background documents [37, 38]. The first stage 
of the process was a desk review that focused on terms 
having programmatic relevance, being related to malaria 
elimination and eradication, and having conflicting defi-
nitions and use. This process was carried out between 
April and May 2015, and resulted in a total of 292 terms 
identified with draft definitions proposed, in some cases 
with an explanatory note. Terms were divided into four 
groups related to elimination, vector control, surveil-
lance, and diagnosis and treatment, with many terms 
relevant to both surveillance and elimination.
These terms and their definitions were then submit-
ted to the members of the WHO Drafting Committee on 
Malaria Terminology who were asked to classify them 
into three groups: (a) terms that were and are still rel-
evant and properly described; (b) terms that have been 
used in the past and have value for historical purposes, 
but are no longer in current use; and (c) terms that are 
relevant today but may have taken on a new meaning and 
different use. After an initial review, the committee was 
convened for a consultation in Geneva on 2–3 Jun 2015, 
to refine all definitions. A concerted effort was made to 
simplify definitions as much as possible, and, as a result, 
the recommended definitions tended to be short with 
an explanatory note to provide qualifying information. 
Following extensive work on the definitions, the draft-
ing committee considered 153 terms as being properly 
described, 38 were proposed for archiving, and 101 terms 
were identified as requiring additional inputs.
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In order to collect additional inputs on these 101 terms 
in a systematic way, WHO-GMP developed an online 
survey and issued a weblink with passcodes that were 
sent to 30 identified institutions or groups. The survey 
was carried out between 6 and 26 Jul 2015, and responses 
were obtained from the majority of institutions on most 
of the survey categories. All inputs were reviewed and 
compiled by the WHO-GMP Secretariat and the sug-
gested modifications then submitted to the WHO Draft-
ing Committee for review by email exchanges. The 
consolidated result of this work in the form of a glossary 
[39] was submitted to MPAC for final review, together 
with specific consideration on the term “malaria case” 
[40], which generated significant debate among the mem-
bers of the Drafting Committee and external reviewers.
MPAC members commended the Drafting Committee 
and WHO-GMP on the rigorous review of malaria ter-
minology that had been conducted in a relatively short 
period of time. MPAC members were asked to advise on 
three issues: advice on malaria case definition [40]; feed-
back on the glossary with proposed terms and definitions 
[39]; and advice on the process for reviewing and incor-
porating new terms. The definition of a “malaria case” 
was debated extensively by MPAC and other attendees. 
The majority felt that there should be one definition 
related to the presence of malaria infection with two 
possible application groups: (1) individuals who present 
with clinical signs and symptoms, and (2) those with 
asymptomatic infection. The Drafting Committee pro-
vided specific advice on the definition of “malaria case” 
with multiple applications in surveillance and for direct-
ing malaria control and elimination efforts. Following the 
contribution by MPAC the definition will be updated and 
a new proposed text will be shared with MPAC members 
before it is finalized.
All present were encouraged to submit suggested edits 
to the glossary to the Drafting Committee via WHO-
GMP. The full glossary of updated terminology will be 
made available for dissemination via the WHO-GMP 
website. For future modifications to the glossary, MPAC 
members suggested that each of the respective TEGs 
should review terminology in their subject areas as an 
ongoing process. The proposed new terms would then be 
shared via the WHO-GMP Secretariat and reviewed by a 
standing WHO Drafting Committee on Malaria Termi-
nology. This Committee would then propose final word-
ing, after which WHO-GMP would add the new terms 
to an on-line glossary on its website. The online glossary 
would be promoted through scientific journals, and with 
members of the global malaria community, to adhere to 
the updated definitions once finalized.
Updates on malaria elimination in the WHO European 
region, the Evidence Review Group on malaria elimination, 
and WHO reform to support innovation, efficiency 
and quality in vector control tools
The final open session of the MPAC meeting featured 
several brief updates for members that were primarily for 
information purposes. These are summarized in brief in 
this section of the report, although the full presentations 
are available along with all other meeting documents 
online [41].
Firstly, an update that drew congratulatory remarks 
from MPAC and other meeting observers, was the 
news that in 2015 there have been no indigenous cases 
of malaria reported in the WHO European region [42]. 
Despite there being an upsurge in cases in the 1990s in 
many countries in the region following the breakup of the 
Soviet Union and a lack of resources for control efforts, 
malaria has been brought under control through the 
reinvigoration of malaria control programmes and pro-
vision of sufficient financial resources to support their 
work. There remains a risk of epidemics in countries 
with large influxes of refugees, such as Turkey, and a risk 
of imported cases from Afghanistan into Tajikistan, but 
certified elimination within the WHO European region is 
now within reach. MPAC commended the countries and 
the Regional Office on their hard work and noted that 
there were several lessons to be learned about the jour-
ney to malaria elimination from the Region’s experience.
The second update concerned malaria elimination and 
the process for certification [43]. WHO-GMP, via an 
ERG, is currently updating its manual of guidelines to 
countries on the elimination process and its certification. 
The new manual will be a major revision of the current 
guidelines since the malaria landscape has changed dra-
matically since the first elimination guidance manual was 
published in 2007 [44]. The updated manual will also be 
aligned with the recently launched WHO Global Tech-
nical Strategy for Malaria (2016–2030). The process of 
updating the elimination manual is progressing well. The 
ERG met for the first time in July 2015, and will meet 
again two more times before the draft manual is reviewed 
by MPAC at its meeting in September 2016. It is based on 
the scenario that all malaria-endemic countries can accel-
erate efforts towards elimination through combinations 
of interventions that are tailored to local contexts, with-
out the restrictions of the phased elimination approach 
currently in use.
In terms of the certification process for elimination, 
MPAC endorsed a plan for a revised and more stream-
lined process to include an increased role for national 
committees as well as MPAC, in collaboration with 
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dedicated team of observers/certifiers who will conduct 
country visits. The new certification process will be out-
lined in more detail in the updated elimination manual.
Finally, MPAC members received an update on WHO 
reform of activities which support innovation in vec-
tor control [45, 46], which is part of a broader process in 
which WHO is one partner. WHO reported that reform 
is underway to improve innovation, to streamline current 
vector control advisory committees at WHO, and make 
more transparent the process for bringing new, effec-
tive, and high-quality vector control products to market. 
The new review committee structure within WHO is still 
being finalized and the transition process will take some 
time, but MPAC members welcomed the change because 
of the benefits it will bring to vector-control product 
manufacturers, national regulatory authorities, the pro-
curement sector, and most importantly, WHO Member 
States and their national malaria control programmes.
Discussion
The wording for recommendations was finalized by 
MPAC during their closed session and, in some cases, 
via email following the meeting; conclusions have been 
included in the summaries of the meeting sessions above, 
and links to the full set of meeting documents from the 
open sessions are provided as references.
Policy recommendations in line with MPAC suggestions 
will be issued formally and disseminated to WHO Mem-
ber States by WHO-GMP and the WHO Regional Offices. 
Conclusions and recommendations from MPAC meetings 
are published in the Malaria Journal as part of this series.
On-going engagement with and attendance by inter-
ested stakeholders at MPAC meetings continues to be 
strong, although it was noted that more can be done 
to publicize open registration, especially to encourage 
attendance by research and development organizations 
who might not otherwise be aware that their presence 
as observers, as with all stakeholders who attend MPAC 
meetings as observers, is most welcome.
Conclusion
WHO-GMP thanked those MPAC members (Salim 
Abdulla, Elfatih Malik, Patricia Graves, and Allan Scha-
pira) who will conclude their service on the committee at 
the end of 2015, and welcomed the new members who will 
be replacing them starting in 2016—Ahmed Adeel, Tom 
Burkot, Gabriel Carrasquilla, Azra Ghani and Gao Qi.
The meeting feedback received from MPAC members, 
participants and observers [47] was generally positive. 
WHO-GMP and MPAC continue to welcome feedback, 
support, and suggestions for improvement of MPAC 
meetings from the global malaria community via the 
WHO-GMP website [9]. The next meeting of the MPAC 
will take place from 16 to 18 March 2016 in Geneva, 
Switzerland. Further information including the agenda 
and registration details will be made available in Janu-
ary 2016 on the MPAC page of the WHO-GMP website, 
although questions are welcome at any time [9].
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